Natera Inc (NTRA) Receives $14.33 Consensus Price Target from Analysts

Natera Inc (NASDAQ:NTRA) has earned an average rating of “Hold” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $14.33.

A number of equities research analysts have issued reports on NTRA shares. BidaskClub downgraded shares of Natera from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 28th. Zacks Investment Research downgraded shares of Natera from a “hold” rating to a “sell” rating in a research note on Tuesday, January 23rd. Finally, Cowen reiterated a “buy” rating and set a $12.00 price objective on shares of Natera in a research note on Thursday, December 21st.

How to Become a New Pot Stock Millionaire

Several institutional investors and hedge funds have recently bought and sold shares of NTRA. Wells Fargo & Company MN boosted its stake in shares of Natera by 2.8% in the 2nd quarter. Wells Fargo & Company MN now owns 18,031 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 491 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Natera by 21.0% in the 2nd quarter. Northern Trust Corp now owns 352,808 shares of the medical research company’s stock valued at $3,831,000 after purchasing an additional 61,226 shares in the last quarter. Voya Investment Management LLC boosted its stake in shares of Natera by 17.8% in the 2nd quarter. Voya Investment Management LLC now owns 14,663 shares of the medical research company’s stock valued at $159,000 after purchasing an additional 2,212 shares in the last quarter. State Street Corp boosted its stake in shares of Natera by 11.8% in the 2nd quarter. State Street Corp now owns 448,708 shares of the medical research company’s stock valued at $4,875,000 after purchasing an additional 47,405 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Natera by 23.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,826 shares of the medical research company’s stock valued at $291,000 after purchasing an additional 5,073 shares in the last quarter. Institutional investors own 67.60% of the company’s stock.

Shares of NTRA stock traded down $0.43 during trading on Wednesday, reaching $9.52. 101,681 shares of the company’s stock were exchanged, compared to its average volume of 153,274. The firm has a market capitalization of $538.61, a P/E ratio of -3.66 and a beta of 2.23. The company has a debt-to-equity ratio of -7.05, a current ratio of 1.37 and a quick ratio of 1.29. Natera has a 12-month low of $7.35 and a 12-month high of $14.76.

WARNING: This piece of content was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3296649/natera-inc-ntra-receives-14-33-consensus-price-target-from-analysts.html.

About Natera

Natera, Inc is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother’s blood and a blood sample from the alleged father(s).

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Set $13.50 Price Target for Manitex International Inc.
Zacks: Analysts Set $13.50 Price Target for Manitex International Inc.
Zacks: Carriage Services, Inc.  Given $32.00 Consensus Target Price by Brokerages
Zacks: Carriage Services, Inc. Given $32.00 Consensus Target Price by Brokerages
Apricus Biosciences  Hits New 12-Month High and Low at $0.25
Apricus Biosciences Hits New 12-Month High and Low at $0.25
Hain Celestial Group  Sets New 12-Month High and Low at $29.83
Hain Celestial Group Sets New 12-Month High and Low at $29.83
EnteroMedics  Sets New 52-Week High and Low at $0.60
EnteroMedics Sets New 52-Week High and Low at $0.60
First Internet Bancorp’s  Buy Rating Reiterated at Maxim Group
First Internet Bancorp’s Buy Rating Reiterated at Maxim Group


© 2006-2018 Ticker Report. Google+.